Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical Trial Not Allowed)
ID: 356952Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356952

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-074.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Combating Antibiotic-Resistant Bacteria Interdisciplinary Units" (CARBIRUs) aimed at supporting multidisciplinary research programs to combat antibiotic-resistant bacterial infections. The initiative seeks to assemble cohesive research teams from various disciplines to enhance understanding of bacterial resistance mechanisms and improve strategies for prevention, diagnosis, and treatment. With a total funding amount of $10 million allocated for 4-5 awards, individual budgets may reach up to $1.5 million per year over a maximum project duration of five years. Interested applicants, including higher education institutions and nonprofits, must submit their proposals through Grants.gov by March 26, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-074-Full-Announcement.html
    RFA-AI-24-074.html
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Combating Antibiotic-Resistant Bacteria Interdisciplinary Units" (CARBIRUs) to support multidisciplinary research programs. The initiative aims to address the growing public health threat posed by antibiotic-resistant bacterial infections, with a focus on discovery research to improve prevention, diagnosis, and treatment strategies. A central goal is to assemble cohesive research teams from diverse disciplines to fill knowledge gaps and enhance understanding of bacterial resistance mechanisms. Funding totaling $10 million is intended for 4-5 awards, with individual budgets expected not to exceed $1.5 million per year over a maximum project period of five years. Eligible applicants include higher education institutions, nonprofits, and government entities, among others. Applications must comply with extensive guidelines and be submitted through Grants.gov by the specified deadlines. The review process will assess significance, innovation, approach, and expertise of the investigators. The CARBIRU program emphasizes collaborative, innovative research and supports efforts aligned with national public health strategies against antibiotic resistance, which contributed to millions of infections and related deaths annually.
    Similar Opportunities
    Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Health Services Research Demonstration and Dissemination Projects aimed at combating Antibiotic-Resistant Bacteria (CARB) under the R18 grant mechanism. The initiative seeks to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections, addressing significant public health concerns with over 2.8 million infections occurring annually in the U.S. Eligible applicants include educational institutions, non-profits, state and local governments, and various organizations focused on healthcare improvements, with funding available up to $500,000 per year for a maximum of five years, totaling no more than $2.5 million. Interested parties should submit their applications by October 30, 2026, and can direct inquiries to GrantQueries@ahrq.hhs.gov for further information.
    Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Research Projects aimed at combating Antibiotic-Resistant Bacteria (CARB). This initiative invites applications for grant funding to enhance appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections across various healthcare settings. With a focus on addressing significant public health threats posed by antibiotic resistance, the grants can fund projects up to $2.5 million over five years, with annual budgets not exceeding $500,000. Interested applicants must adhere to detailed submission guidelines, and the application deadline is October 30, 2026. For further inquiries, applicants can contact AHRQ at GrantQueries@ahrq.hhs.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (PAR-25-107). This initiative invites grant applications that explore the use of bacteria, archaebacteria, bacteriophages, and non-oncolytic viruses to investigate their interactions with tumors and the immune system, aiming to develop innovative strategies for cancer imaging and therapy, particularly for oral cancers. The program encourages multidisciplinary collaboration among experts in microbiology, cancer biology, and immunology to address challenges associated with solid tumors and metastases. Applications will be accepted starting January 5, 2025, with no budget limit, and the project period can extend up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R01 Clinical Trial Not Allowed), aimed at advancing research on the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between bacteria, archaebacteria, bacteriophages, and tumors, focusing on their potential to enhance cancer imaging, therapeutics, and diagnostics, particularly for solid tumors. The program encourages multidisciplinary collaborations and aims to address current limitations in cancer therapies, with a significant emphasis on improving treatment outcomes in low-resource settings. Interested applicants can find more information and submit their proposals by May 7, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R21 Clinical Trial Not Allowed), aimed at advancing research in the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between microorganisms, tumors, and the immune system, focusing on their potential to develop innovative strategies for cancer imaging and therapeutics, particularly for solid tumors and oral cancers. The program supports exploratory and developmental research with a maximum budget of $275,000 over two years, encouraging multidisciplinary collaboration to address significant challenges in cancer therapy. Applications are due by May 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the NARMS Cooperative Agreement Program, aimed at strengthening antibiotic resistance surveillance in retail food specimens. This initiative seeks to enhance the National Antimicrobial Resistance Monitoring System (NARMS) by improving the detection of antibiotic resistance among bacteria in food commodities and expanding sampling efforts to new sites. The program is critical for public health as it addresses the growing threat of antibiotic resistance, ensuring better monitoring and response strategies. Interested applicants can apply for a total funding amount of up to $4.5 million, with an expected 30 awards available, and should contact Terrin Brown at terrin.brown@fda.hhs.gov or 240-402-7610 for further details.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)" aimed at supporting innovative mechanistic research to develop precision probiotic interventions. This initiative seeks to identify person-specific biological features that influence probiotic responses, thereby enhancing clinical outcomes and addressing the variability in individual responses to probiotics. The funding, which can reach a maximum of $350,000 annually over a combined duration of up to five years, is open to a diverse range of applicants, including educational institutions and nonprofit organizations, while excluding foreign entities. Interested applicants must submit their proposals by June 2, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced the Cutting-Edge Basic Research Awards (CEBRA) aimed at promoting innovative research in the field of substance use disorders (SUDs). This funding opportunity invites exploratory applications that focus on high-risk, high-impact research not currently represented in NIDA’s portfolio, encouraging the development of revolutionary methodologies or the testing of transformative hypotheses. The program seeks to stimulate novel insights into the etiology and treatment of SUDs by integrating diverse scientific disciplines, with a maximum budget of $275,000 for each two-year project, allowing no more than $150,000 to be requested in a single year. Applications are due by February 10, 2025, and the funding opportunity will remain open until August 12, 2027; for further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.